Terrie Curran has served as a member of our board of directors since November 2020. Ms Curran is CEO and president at Phathom Pharmaceuticals (Nasdaq: PHAT), a late-clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases. Prior to this, she was the president, global inflammation and immunology (I&I) franchise and member of the executive committee at Celgene. She joined Celgene in 2013 as the US commercial head of the I&I franchise and built the capabilities and recruited the teams that executed the successful launch of Otezla® for moderate-to-severe plaque psoriasis. Prior to joining Celgene, she served as senior vice president and general manager, global women’s health at Merck & Co. Ms Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.